Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation

被引：94

作者：

Bradley, JS ^{[1
]}

Dudley, MN

Drusano, GL

机构：

[1] Childrens Hosp, Div Infect Dis, San Diego, CA 92123 USA

[2] Diversa Corp, Preclin Res & Dev, San Diego, CA USA

[3] New York State Dept Hlth, Ordway Res Inst & Res Phys, New York, NY USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2003年 / 22卷 / 11期

关键词：

antimicrobial therapy; pharmacodynamics; pharmacokinetics; Monte Carlo simulation;

D O I：

10.1097/01.inf.0000094940.81959.14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：982 / 992

页数：11

共 27 条

[1] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].

Ambrose, PG ;

Grasela, DM ;

Grasela, TH ;

Passarell, J ;

Mayer, HB ;

Pierce, PF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797

[2] Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models [J].

Andes, D ;

Craig, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1665-1670

[3] Management of fever without source in infants and children [J].

Baraff, LJ .

ANNALS OF EMERGENCY MEDICINE, 2000, 36 (06) :602-614

[4] Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media [J].

Blumer, JL .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (11) :1070-1075

[5]

Craig W A, 1990, Scand J Infect Dis Suppl, V74, P63

[6] Pharmacokinetics and pharmacodynamics of antibiotics in otitis media [J].

Craig, WA ;

Andes, D .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (03) :255-259

[7] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10

[8] Prevention of resistance: A goal for dose selection for antimicrobial agents [J].

Drusano, GL .

CLINICAL INFECTIOUS DISEASES, 2003, 36 :S42-S50

[9] Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint [J].

Drusano, GL ;

Preston, SL ;

Hardalo, C ;

Hare, R ;

Banfield, C ;

Andes, D ;

Vesga, O ;

Craig, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :13-22

[10] PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].

DRUSANO, GL ;

JOHNSON, DE ;

ROSEN, M ;

STANDIFORD, HC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490

← 1 2 3 →